Genmab A/S (GMAB) Projected to Post Earnings on Thursday

Posted by Brenda Bartman on Oct 29th, 2026

Genmab A/S (NASDAQ:GMAB – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.37 per share and revenue of $1.20 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 12:00 PM ET.

Genmab A/S (NASDAQ:GMAB – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.12 billion. On average, analysts expect Genmab A/S to post $1.22 EPS for the current fiscal year and $1.59 EPS for the next fiscal year.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $57.29 on Thursday. The company’s fifty day moving average is $36.20 and its two-hundred day moving average is $30.36. The company has a market cap of $35.75 billion, a P/E ratio of 45.11, a price-to-earnings-growth ratio of 2.01 and a beta of 0.81. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $59.97. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. TD Cowen raised their target price on Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday. JPMorgan Chase & Co. raised Genmab A/S from a “neutral” rating to an “overweight” rating in a research report on Monday. Truist Financial upped their price target on Genmab A/S from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. HC Wainwright increased their price objective on Genmab A/S from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Finally, Guggenheim raised their price objective on Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.39.

Get Our Latest Analysis on GMAB

Trending Headlines about Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

Positive Sentiment: Genmab reported that the Phase 3 LiGeR-HN1 trial met both primary endpoints in first-line, PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma. Petosemtamab combined with Merck’s pembrolizumab reduced the risk of death by 50% versus pembrolizumab alone, with a statistically significant improvement in overall survival and objective response rate, regardless of patients’ HPV status. Genmab Phase 3 trial announcement
Positive Sentiment: The results support expectations that petosemtamab could become a meaningful commercial product and potentially establish a new treatment standard. Analysts described the results as a significant “hat trick,” while reports highlighted the drug’s potential in combination with Keytruda. Barron’s report on Genmab’s record high
Positive Sentiment: JPMorgan upgraded its rating on GMAB, and TD Cowen said the stock could rise, adding to the positive analyst sentiment. Heavy call-option activity also indicates strong speculative interest following the clinical announcement. JPMorgan rating upgrade
Neutral Sentiment: Genmab plans to discuss the results with global regulators and submit the full dataset for presentation at a future medical meeting. Investors still lack the complete efficacy and safety details, and regulatory approval and commercialization remain ahead. Genmab Phase III data discussion

About Genmab A/S

(Get Free Report)

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.